# Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)

> **NCT06962332** · PHASE1 · RECRUITING · sponsor: **Exelixis** · enrollment: 20 (estimated)

## Conditions studied

- Hepatic Impairment
- Moderate Hepatic Impairment

## Interventions

- **DRUG:** Zanzalintinib

## Key facts

- **NCT ID:** NCT06962332
- **Lead sponsor:** Exelixis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-13
- **Primary completion:** 2025-12
- **Final completion:** 2026-04
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06962332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06962332, "Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06962332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*